Major Histocompatibility Complex class II-peptide complex (MHC II-peptide complex)

The Major Histocompatibility Complex (MHC) class II-peptide complex on autologous dendritic cells is a specialized molecular assembly essential for the initiation of adaptive immune responses. Dendritic cells, acting as professional antigen-presenting cells, process exogenous proteins into short peptides and load them onto MHC class II molecules (such as HLA-DR, HLA-DQ, and HLA-DP) for presentation on the cell surface [1, 3]. This complex is specifically recognized by the T-cell receptor (TCR) of CD4+ helper T cells, providing the primary signal required for T-cell activation and the subsequent coordination of B-cell and CD8+ T-cell activity [2]. In the context of cancer immunotherapy, autologous dendritic cells are often pulsed with tumor-associated antigens to form these complexes, which then serve as a personalized vaccine to prime the patient's immune system against malignant cells [4, 7]. Beyond vaccines, the MHC II-peptide complex is an emerging target for TCR-mimic antibodies and engineered T-cell therapies designed to recognize intracellular antigens presented on the cell surface [5]. Therapeutic challenges include the extreme polymorphism of the HLA system, which necessitates patient-specific matching, and the potential for off-target autoimmunity if the presented peptide is derived from a self-protein [4, 6].

Other names

HLA class II-peptide complexpMHCIIMHC II-antigen complexPeptide-MHC II complexAntigen-MHC II complex

The MHC class II-peptide complex acts as a ligand for the T-cell receptor (TCR) on CD4+ T lymphocytes. Upon binding, it facilitates the formation of the immunological synapse, leading to the phosphorylation of CD3 chains and subsequent activation of downstream signaling pathways (e.g., ZAP-70, LAT) that drive T-cell proliferation, cytokine secretion, and immune orchestration [1, 3].